Impurities test for Trimethoprim (EP-8.0 method) - For Impurities-H & I

Significance of the Topic

Assessing impurities in active pharmaceutical ingredients is critical for ensuring drug safety, efficacy, and regulatory compliance. The European Pharmacopoeia method for quantifying Trimethoprim impurities H and I provides a standardized protocol to monitor trace-level contaminants that could impact product quality.

Study Objectives and Overview

The main goal of the study was to validate the European Pharmacopoeia (EP) 8.0 procedure for determining impurities H and I in Trimethoprim. The overview covers sample preparation, chromatographic conditions, system suitability assessment, and result interpretation under EP guidelines.

Methodology

The analytical procedure involves:

• Preparing a test solution by dissolving 25 mg of Trimethoprim in mobile phase and diluting to 25 mL.
• Preparing reference solution (a) by diluting 1 mL of test solution to 200 mL with mobile phase.
• Preparing reference solution (b) by dissolving 5 mg each of Trimethoprim and Impurity-B in mobile phase and diluting to 100 mL.
• Performing isocratic reversed-phase chromatography at 25 °C using a cyanopropyl column and phosphate buffer/methanol mobile phase at pH 3.1.
• Detecting analytes with UV at 280 nm over a 30-minute run time.

Used Instrumentation

The following instrumentation was employed:

• Liquid Chromatograph: UltiMate 3000 LC
• Column: Betasil-CN (4.6 × 250 mm, 5 µm)
• Detector: UV set to 280 nm

Main Results and Discussion

System suitability tests confirmed method performance:

• Resolution between Trimethoprim and Impurity B: criterion ≥ 2.0; obtained 5.9.
• Relative retention time (RRT) of Impurity H vs. Trimethoprim: expected ≈ 1.8; obtained 1.8.

Impurity I was not available at the time of analysis, so only Impurity H was assessed. The observed RRT for Impurity H met EP specifications, demonstrating method selectivity and precision.

Benefits and Practical Applications

This validated EP method enables pharmaceutical quality control laboratories to:

• Accurately quantify key impurities in Trimethoprim batches.
• Ensure compliance with pharmacopeial standards.
• Support stability studies by monitoring impurity profiles over time.

Future Trends and Potential Uses

Emerging directions include:

• Adoption of UHPLC formats to reduce run times and solvent consumption.
• Integration with mass spectrometric detection for enhanced impurity identification.
• Application of automated data analysis and machine learning for trend monitoring.

Conclusion

The EP-8.0 method for Trimethoprim impurities H and I has been successfully applied, meeting all system suitability criteria. Although Impurity I was unavailable, the validated procedure reliably detects Impurity H with high resolution and consistent retention time, ensuring robust impurity monitoring.

References

European Pharmacopoeia 8.0. Monograph for Trimethoprim Impurities Assay.